Researchers at Baycrest Hospital in Toronto are testing a decades-old drug to treat paratonia, a symptom of advanced dementia causing uncontrollable muscle stiffness [1, 2].
This research is significant because paratonia is frequently misinterpreted by caregivers as purposeful resistance. By identifying a medical treatment for this stiffness, clinicians may improve the quality of daily care, and reduce the physical and emotional strain on families [1, 2].
Dr. Galit Klei, a researcher at the geriatric care center, said the condition creates a misleading perception of the patient's intent. "It'll appear that they are actively resisting any attempt to move their limb when in fact it's a reflex and they have no voluntary control over it," Klei said [1].
Paratonia occurs in the advanced stages of dementia and manifests as a rigid response to movement. Because the stiffness is a reflex, patients cannot consciously relax their muscles. This often leads to difficulties during routine tasks such as dressing or bathing, processes that become stressful for both the patient and the provider [1, 2].
The experimental research focuses on repurposing an existing medication to ease these symptoms. The goal is to reduce the involuntary muscle tension that characterizes the condition. If successful, the treatment could provide a new standard of care for those in the late stages of cognitive decline [1, 2].
Baycrest Hospital continues to lead the study in Toronto, focusing on the intersection of geriatric medicine and neurological reflexes [1, 2].
“It'll appear that they are actively resisting any attempt to move their limb”
The focus on paratonia highlights a critical gap in dementia care where physical symptoms are often misattributed to behavioral issues. Moving from a behavioral interpretation to a medical one allows for pharmacological interventions that can improve the physical dignity and comfort of patients in advanced stages of the disease.
